$750 Million is the total value of Paradigm Biocapital Advisors LP's 28 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 65.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $80,077,000 | +73.4% | 1,175,879 | -18.7% | 10.68% | +15.9% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $59,391,000 | +34.1% | 850,385 | +28.9% | 7.92% | -10.4% |
| INCY | Buy | INCYTE CORP | $51,518,000 | +22.0% | 773,082 | +39.0% | 6.87% | -18.5% |
| ASND | Buy | ASCENDIS PHARMA A/Ssponsored adr | $51,356,000 | +27.8% | 497,347 | +15.1% | 6.85% | -14.5% |
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $43,925,000 | -18.4% | 1,076,591 | +10.0% | 5.86% | -45.4% |
| BIIB | New | BIOGEN INC | $41,280,000 | – | 154,605 | +100.0% | 5.50% | – |
| BIIB | New | BIOGEN INCcall | $40,050,000 | – | 150,000 | +100.0% | 5.34% | – |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $36,288,000 | +45.7% | 773,079 | +15.8% | 4.84% | -2.6% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $33,559,000 | +122.0% | 1,636,211 | +25.2% | 4.47% | +48.4% |
| ARGX | Buy | ARGENX SEsponsored adr | $31,879,000 | -5.3% | 90,297 | +1.7% | 4.25% | -36.7% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $29,431,000 | -23.4% | 140,561 | -13.8% | 3.92% | -48.8% |
| AKRO | New | AKERO THERAPEUTICS INC | $28,373,000 | – | 833,265 | +100.0% | 3.78% | – |
| BCYC | Buy | BICYCLE THERAPEUTICS PLCsponsored ads | $26,951,000 | +53.2% | 1,158,686 | +10.5% | 3.59% | +2.4% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $26,076,000 | +54.7% | 1,085,142 | +23.9% | 3.48% | +3.4% |
| AXSM | New | AXSOME THERAPEUTICS INC | $23,206,000 | – | 520,080 | +100.0% | 3.09% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $21,748,000 | – | 351,405 | +100.0% | 2.90% | – |
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $15,946,000 | +126.6% | 2,214,722 | +167.9% | 2.13% | +51.5% |
| PRTA | New | PROTHENA CORP PLC | $14,298,000 | – | 235,826 | +100.0% | 1.91% | – |
| ARVN | Sell | ARVINAS INC | $12,625,000 | -42.0% | 283,777 | -45.2% | 1.68% | -61.2% |
| ESPR | Buy | ESPERION THERAPEUTICS INC NE | $11,523,000 | +28.7% | 1,719,831 | +22.1% | 1.54% | -14.0% |
| MRUS | Buy | MERUS N V | $11,301,000 | +10.4% | 564,214 | +24.8% | 1.51% | -26.2% |
| GTHX | New | G1 THERAPEUTICS INC | $11,048,000 | – | 884,574 | +100.0% | 1.47% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $10,198,000 | – | 519,256 | +100.0% | 1.36% | – |
| OYST | Buy | OYSTER PT PHARMA INC | $9,264,000 | +60.5% | 1,648,316 | +23.6% | 1.24% | +7.3% |
| TGTX | Sell | TG THERAPEUTICS INC | $8,912,000 | +6.7% | 1,505,479 | -23.4% | 1.19% | -28.6% |
| PSTX | New | POSEIDA THERAPEUTICS INC | $7,307,000 | – | 2,070,108 | +100.0% | 0.97% | – |
| VOR | Buy | VOR BIOPHARMA INC | $6,781,000 | +4.6% | 1,703,645 | +30.6% | 0.90% | -30.0% |
| MIST | New | MILESTONE PHARMACEUTICALS IN | $5,828,000 | – | 634,211 | +100.0% | 0.78% | – |
| CCCC | Exit | C4 THERAPEUTICS INC | $0 | – | -73,149 | -100.0% | -0.11% | – |
| LQDA | Exit | LIQUIDIA CORPORATION | $0 | – | -850,961 | -100.0% | -0.74% | – |
| GRCL | Exit | GRACELL BIOTECHNOLOGIES INCsponsored ads | $0 | – | -783,445 | -100.0% | -0.86% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -148,216 | -100.0% | -1.40% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -801,314 | -100.0% | -8.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.